Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Breast cancer, metastatic

2333 - Anti-tumor activity of PM01183 (lurbinectedin) in BRCA1/2-associated metastatic breast cancer patients: results of a single-agent phase II trial


08 Oct 2016


Breast cancer, metastatic


Judith Balmaña


Annals of Oncology (2016) 27 (6): 68-99. 10.1093/annonc/mdw365


J. Balmaña1, C. Cruz1, B.K. Arun2, M. Telli3, J. Garber4, S. Domchek5, C.M. Fernandez6, C. Kahatt6, S. Szyldergemajn6, A. Soto-Matos6, A. Perez de la Haza6, J.A. Perez Fidalgo7, A. Lluch-Hernandez7, S. Antolin8, N.M. Tung9, L.T. Vahdat10, R. Lopez11, S.J.J. Isakoff12

Author affiliations

  • 1 Medical Oncology, Hospital Vall d’Hebron and Vall d’Hebron Institute of Oncology, 08035 - Barcelona/ES
  • 2 Breast Medical Oncology, MD Anderson Cancer Center, 77030 - Houston/US
  • 3 Medical Oncology, Stanford University Medical Center, Stanford/US
  • 4 Medical Oncology, Dana Farber Cancer Institute, Boston/US
  • 5 Medical Oncology, Hospital of the University of Pennsylvania, Philadelphia/US
  • 6 Clinical Development, PharmaMar SA, 28770 - Colmenar Viejo/ES
  • 7 Medical Oncology, Hospital Clinico Universitario de Valencia, Valencia/ES
  • 8 Medical Oncology, Complejo Universitario Hospitalario La Coruña, A Coruna/ES
  • 9 Medical Oncology, Beth Israel Deaconess Medical Center, Boston/US
  • 10 Medical Oncology, Weill Cornell Medicine, New York/US
  • 11 Medical Oncology, Complejo Hospitalario Universitario de Santiago de Compostela, 15706 - Santiago de Compostela/ES
  • 12 Medical Oncology, Massachusetts General Hospital, Boston/US


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 2333


PM01183 (lurbinectedin) is a new anticancer drug that blocks trans-activated transcription, induces DNA double-strand breaks and modulates the tumor microenvironment. PM01183 activity has been observed in different tumor types, and in patients resistant to platinum-based chemotherapy (CT). The activity observed against homologous-recombination-deficient cell lines prompted a phase II trial in metastatic breast cancer (MBC) patients (pts) with deleterious germline BRCA mutations (BRCA+).


BRCA+ MBC pts pretreated with ≤ 3 CT regimens in the advanced/metastatic setting, measurable disease per RECIST v1.1, performance status (PS) ≤ 1, and adequate major organ function were treated with PM01183 IV q3wk. A protocol amendment adjusted the starting dose from 7 mg fixed dose (FD) to 3.5 mg/m2 to improve safety. Primary endpoint was overall response rate (ORR) by RECIST v1.1 with further development of PM01183 if ≥ 17 responses of 53 evaluable pts were confirmed.


As of May 2016, 54 eligible pts (median age 43 years, median 1 prior advanced CT) have been treated (35 with 7 mg FD; 19 with 3.5 mg/m2). PS 0: 30 pts; prior anthracyclines: 45 pts, taxanes: 47 pts, platinum: 27 pts, PARP inhibitors: 9 pts; >2 metastatic sites: 33; BRCA 1: 30 pts; triple negative: 31 pts.

Median cycles (range) 4 (1–24)
Best overall response n = 51 evaluable
CR 1 (2%)
PR 19 (37%)
SD 22 (43%)
PD 9 (18%)
ORR (95%CI) 39% (26–54) 37 / 44% (7 mg FD / 3.5 mg/m2)
- Platinum pretreated 23% (9–44)
Median duration of response months (95%CI) 4.6 (3.4–11.3)
Progression-free survival months (95%CI) 4.1+ (2.6–6.0)

Most common grade (G) 3–4 related adverse events (7 mg FD / 3.5 mg/m2) were (%): neutropenia 71 / 50 (G4: 51/6); febrile neutropenia 29 / 6; thrombocytopenia 26 / 6 (G4; 20/0); G3 fatigue 17 / 17; transaminase increase 26 / 11 (G4; 3/0); and G3 nausea 9 / 6.


Primary endpoint was met. PM01183 is an active drug in BRCA+ MBC, regardless of prior platinum treatment. At 3.5 mg/m2, the tolerance improved notably, while maintaining the efficacy. Further development is warranted in this indication and a Phase 3 trial is planned.

Clinical trial identification


Legal entity responsible for the study

PharmaMar S.A.


PharmaMar S.A.


J. Balmaña: Receipt of grants / research supports; PharmaMar. Paticipation in a company sponsored speaker's bureau; AstraZeneca.

C.M. Fernandez: PharmaMar employee. C. Kahatt, S. Szyldergemajn, A. Soto-Matos: PharmaMar employee and stock ownership. A. Perez de la Haza: PharmaMar employee. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings